{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:09:37Z","timestamp":1780646977848,"version":"3.54.1"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"abstract":"<jats:p>\n                    The occurrence of secondary cutaneous manifestations in peripheral T-cell lymphoma (PTCL) is relatively infrequent and can resemble benign dermatoses, leading to diagnosis delays. We present the case of a 78-year-old female patient with a diagnosis of PTCL affecting the left parotid gland, who experienced a 2-day sudden and intensely pruritic skin eruption, which progressed from both forearms to the trunk, involving more than 50% of the total body surface area. Initially, the eruption was managed as a hypersensitivity reaction with antihistamines and corticosteroids, with temporary symptomatic relief; however, the rapid clinical progression in the context of an established diagnosis of PTCL raised suspicion of secondary cutaneous involvement. Previous pathological examinations indicated a mature T-cell phenotype (CD2\n                    <jats:sup>+<\/jats:sup>\n                    \/CD3\n                    <jats:sup>+<\/jats:sup>\n                    \/CD5\n                    <jats:sup>+<\/jats:sup>\n                    \/TCR\u03b2F1\n                    <jats:sup>+<\/jats:sup>\n                    ), partial expression of CD4, loss of CD7 in larger cells, minimal CD30 expression (10%), and a high proliferative index (Ki-67 70%). Imaging studies demonstrated persistent disease in the parotid gland and partially necrotic cervical lymph nodes, without evidence of distant metastasis. Considering significant cardiac comorbidities and CD30 expression, an anthracycline-sparing, CD30-targeted therapeutic approach was chosen. Treatment with brentuximab vedotin yielded early alleviation of pruritus and progressive resolution of lesions by the third cycle, with favorable tolerability. This case serves as a foundation for a narrative review that underscores the diagnostic challenges associated with \u201callergic-appearing\u201d eruptions in patients with T-cell lymphoma, the importance of integrated staging utilizing TNMB (skin\/blood) in conjunction with Lugano\/Deauville positron emission tomography\u2013computed tomography to assess systemic burden and therapeutic response, and biologically informed systemic therapy options aligned with comorbidities, including emerging targeted treatment strategies.\n                  <\/jats:p>","DOI":"10.1177\/10815589261455327","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:28:02Z","timestamp":1780396082000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Secondary cutaneous involvement in peripheral T-cell lymphoma: Diagnostic frameworks, staging integration, and therapeutic implications"],"prefix":"10.1177","author":[{"given":"Aura","family":"Calderon","sequence":"first","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Loayza","family":"Pintado","sequence":"additional","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Kochi","sequence":"additional","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Hensley","sequence":"additional","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Suarez","family":"Parraga","sequence":"additional","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo","family":"Cobos","sequence":"additional","affiliation":[{"name":"University of Texas Rio Grande Valley School of Medicine, Department of Internal Medicine, Edinburg, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"issue":"1","key":"e_1_3_2_5_2","article-title":"Beyond the rash: cutaneous peripheral T-cell lymphoma as a diagnostic pitfall in primary care","volume":"18","author":"Hensley J","year":"2026","unstructured":"Hensley J, Calderon A, Martin BC, et al. Beyond the rash: cutaneous peripheral T-cell lymphoma as a diagnostic pitfall in primary care. Cureus 2026; 18(1): e102378.","journal-title":"Cureus"},{"issue":"2","key":"e_1_3_2_6_2","first-page":"585","article-title":"Baron Jean-Louis Alibert (1768\u20131837) and the first description of mycosis fungoides","volume":"19","author":"Karamanou M","year":"2014","unstructured":"Karamanou M, Antoniou C, Panayiotakopoulos G, et al. Baron Jean-Louis Alibert (1768\u20131837) and the first description of mycosis fungoides. J BUON 2014; 19(2): 585\u2013587.","journal-title":"J BUON"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-83-4-534"},{"issue":"11","key":"e_1_3_2_8_2","article-title":"Early-stage mycosis fungoides: epidemiology and prognosis","volume":"100","author":"Maguire A","year":"2020","unstructured":"Maguire A, Puelles J, Raboisson P, et al. Early-stage mycosis fungoides: epidemiology and prognosis. Acta Derm Venereol 2020; 100(11): adv00199.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"e_1_3_2_9_2","first-page":"1732","article-title":"Outcomes and prognostic factors in African American patients with mycosis fungoides and S\u00e9zary syndrome","volume":"11","author":"Geller S","year":"2019","unstructured":"Geller S, Myskowski PL, Pulitzer MP, et al. Outcomes and prognostic factors in African American patients with mycosis fungoides and S\u00e9zary syndrome. Cancers 2019; 11(11): 1732.","journal-title":"Cancers"},{"issue":"10","key":"e_1_3_2_10_2","first-page":"1242","article-title":"Evidence for human T-cell leukemia virus type I associated with mycosis fungoides","volume":"122","author":"Peterman GM","year":"1986","unstructured":"Peterman GM, Hassell LH, Raimer SS, et al. Evidence for human T-cell leukemia virus type I associated with mycosis fungoides. Arch Dermatol 1986; 122(10): 1242\u20131246.","journal-title":"Arch Dermatol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24826"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00732-w"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"issue":"4","key":"e_1_3_2_15_2","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines","volume":"29","author":"Willemze R","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines. Ann Oncol 2018; 29(suppl 4): iv30\u2013iv40.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz021"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1474"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2021.02.004"},{"key":"e_1_3_2_25_2","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, counteracts PIM1-driven NF-\u03baB\/STAT in CTCL","author":"Seto AG","year":"2018","unstructured":"Seto AG, Beatty X, Lynch J, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, counteracts PIM1-driven NF-\u03baB\/STAT in CTCL. Sci Transl Med 2018.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119861"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_3_2_28_2","first-page":"2778","article-title":"Pembrolizumab in relapsed\/refractory MF\/SS (CITN-10)","volume":"37","author":"Khodadoust MS","year":"2019","unstructured":"Khodadoust MS, Rook A, Porcu P, et al. Pembrolizumab in relapsed\/refractory MF\/SS (CITN-10). J Clin Oncol 2019; 37: 2778\u20132789.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_29_2","first-page":"13","article-title":"Immune checkpoint inhibitors in primary CTCL: biology and clinical data","author":"Roccuzzo G","year":"2021","unstructured":"Roccuzzo G, Giordano S, Fava P, et al. Immune checkpoint inhibitors in primary CTCL: biology and clinical data. Cancers 2021; 13.","journal-title":"Cancers"},{"key":"e_1_3_2_30_2","article-title":"Hyperprogression of CTCL after anti-PD-1 therapy: PD-1 as tumor suppressor in malignant T cells","volume":"8","author":"Gao Y","year":"2023","unstructured":"Gao Y, Hu S, Li R, et al. Hyperprogression of CTCL after anti-PD-1 therapy: PD-1 as tumor suppressor in malignant T cells. JCI Insight 2023; 8: e164793.","journal-title":"JCI Insight"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3706"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1297"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/life14020245"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30320-1"},{"key":"e_1_3_2_36_2","first-page":"2024","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immutherapy represent the best chance of cure?","author":"Maciocia N","unstructured":"Maciocia N, Wade B, Maciocia P, et al. CAR T-cell therapies for T-cell malignancies: does cellular immutherapy represent the best chance of cure? Blood Adv2024\u20132025.","journal-title":"Blood Adv"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1913"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03640-8"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102921"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.729831"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.12.017","article-title":"Racial disparities in mycosis fungoides\/S\u00e9zary syndrome","volume":"24","author":"Gandham AR","year":"2024","unstructured":"Gandham AR, Marshall A, Ma J, et al. Racial disparities in mycosis fungoides\/S\u00e9zary syndrome. Clin Lymphoma Myeloma Leuk 2024; 24: e174\u2013e180.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3601"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae039"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2634"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19669"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043578"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06109-9"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.046"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261455327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589261455327","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261455327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:48:06Z","timestamp":1780645686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589261455327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":47,"alternative-id":["10.1177\/10815589261455327"],"URL":"https:\/\/doi.org\/10.1177\/10815589261455327","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"10815589261455327"}}